Cost and Accessibility
The initial costs of DNA nanobot therapies are expected to be high due to complex manufacturing and development. However, as technology advances and production methods scale up, prices should decrease over time. Global accessibility will depend on partnerships between governments, researchers, and pharmaceutical companies. Efforts are already underway to streamline processes and develop affordable versions, aiming to ensure that innovative cancer treatments reach patients in both developed and resource-limited settings worldwide.